Nebido® - The only long-acting injectabletestosterone replacement therapy (TRT)

Hypogonadism (testosterone deficiency)

Male hypogonadism is a clinical syndrome resulting from a failure of the testes to produce physiological levels of testosterone (androgen deficiency), sperm, or both, because of disruption of one or more levels of the hypothalamic-pituitary-gonadal axis.

Find out more
Testosterone conversion
Free testosterone calculator
Testosterone management tool
Testosterone effects tool

Testosterone tools

Try out our four helpful Testosterone Tools. They make it much easier to manage the treatment of hypogonadism. These tools allow for easy testosterone conversion and free testosterone calculation, provide an algorithm for diagnosis and treatment of hypogonadism, and a visualization of when each of the many beneficial testosterone effects can be expected to manifest.

Find out more

Testosterone replacement therapy (TRT)

The essential aim of testosterone replacement therapy is to restore serum testosterone to the middle of the normal physiological range and to minimize the signs and symptoms of hypogonadism.

Icon

Treatment guidelines

Guidelines and recommendations issued by medical societies on the definition, investigation, treatment and follow-up of men with late-onset hypogonadism.

Find out more
Icon

Nebido® product information

Long term treatment therapy with Nebido® increases the improvement of erectile dysfunction, sexual mood, metabolic syndrome, muscle mass and strength.   

Find answers to treatment, advantages, dosage and side effects of using Nebido®.

Find out more

Latest news on men's health matters

Nebido® Treatment Tracker

15 June 2019

Nebido® treatment tracker
Read more
 Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes

16 May 2019

Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes
Read more
Testosterone therapy to prevent type 2 diabetes in men at risk - rationale

15 May 2019

Testosterone therapy to prevent type 2 diabetes in men at risk - rationale
Read more
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Tue, 15/10/2019

Bayer logo